Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Repolarization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Repolarization. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-005082-47 Sponsor Protocol Number: HUS/1209/2017 Start Date*: 2018-09-24
    Sponsor Name:Sydän- ja keuhkokeskus, HUS
    Full Title: Repolarization study in LQTS patients
    Medical condition: Long QT syndrome (LQTS) is a hereditary arrhythmia disease. It causes disturbances to the ion flow through cell membranes of cardiomyocytes. These disturbances can sometimes seen in an electrocardi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000206-18 Sponsor Protocol Number: PM1183-B-005-14-QT Start Date*: 2015-09-10
    Sponsor Name:PharmaMar S.A., Sociedad Unipersonal
    Full Title: Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients with Selected Solid Tumors
    Medical condition: - small cell lung cancer (SCLC) - head and neck carcinoma (H&N) - neuroendocrine tumors (NETs) - biliary tract carcinoma - endometrial carcinoma - BRCA 1/2-associated metastatic breast carcinoma - ...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005292-14 Sponsor Protocol Number: not_applicable Start Date*: 2013-01-09
    Sponsor Name:Heikki Swan
    Full Title: Dantrolene in catecholaminiergic polymorphic ventricular tachycardia
    Medical condition: Catecholaminergic polymorphic ventricular tachycardia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10036095 Polymorphic ventricular tachycardia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001853-89 Sponsor Protocol Number: CLI-043 Start Date*: 2006-07-07
    Sponsor Name:Vion Pharmaceuticals, Inc
    Full Title: A phase II study of Cloretazine for elderly patients with de novo poor risk acute myelogenous leukemia.
    Medical condition: Acute Myelogenous Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002874-19 Sponsor Protocol Number: 63935937MDS3001 Start Date*: 2015-11-23
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Sti...
    Medical condition: Myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003385-84 Sponsor Protocol Number: GO40782(RXDX-101-02) Start Date*: 2016-03-15
    Sponsor Name:F. Hoffman-La Roche Ltf
    Full Title: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRA...
    Medical condition: Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004371-22 Sponsor Protocol Number: ADN009 Start Date*: 2015-01-12
    Sponsor Name:ADIENNE SA
    Full Title: Phase IV study to assess, the effect of hepatic impairment on the pharmacokinetics of Thiotepa and the potential of Thiotepa to alter the QT interval in pedatric patients undergoing allogeneic haem...
    Medical condition: Patients with various hematological disease requiring Bone Marrow Transplantation, with Child-Pugh score A and B
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022951-49 Sponsor Protocol Number: 20100007 Start Date*: 2011-06-06
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefracto...
    Medical condition: Chemorefractory, Wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS), Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) EE (Completed) LV (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004852-77 Sponsor Protocol Number: GO29642 Start Date*: 2015-05-27
    Sponsor Name:Genentech, Inc
    Full Title: AN OPEN-LABEL, PHASE I/IIA STUDY OF GDC-0810 IN POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR POSITIVE BREAST CANCER
    Medical condition: Patients with locally advanced or metastatic estrogen receptor (ER) positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000381-20 Sponsor Protocol Number: 27820 Start Date*: 2007-11-16
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) GB (Completed) CZ (Completed) BE (Completed) EE (Completed) AT (Completed) PT (Completed) NL (Completed) DE (Completed) DK (Completed) IT (Completed) GR (Completed) LV (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-006950-81 Sponsor Protocol Number: KTN32313R Start Date*: 2007-09-25
    Sponsor Name:BioNumerik Pharmaceuticals, Inc.
    Full Title: A PHASE 3 STUDY OF SAFETY AND EFFICACY OF KARENITECIN VERSUS TOPOTECAN ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER
    Medical condition: advanced epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002283-16 Sponsor Protocol Number: 1P50HL112349 Start Date*: 2016-03-08
    Sponsor Name:National Heart, Lung, and Blood Institute / National Institutes of Health
    Full Title: Phase II randomized, placebo-controlled, double blind clinical trial of valsartan for attenuating disease evolution in early sarcomeric HCM
    Medical condition: Hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10020204 HOCM Hypertrophic obstructive cardiomyopathy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-010788-18 Sponsor Protocol Number: CAMMS03409 Start Date*: 2009-07-01
    Sponsor Name:Genzyme Corporation
    Full Title: An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) SE (Completed) AT (Completed) PL (Completed) CZ (Completed) NL (Completed) DK (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000158-88 Sponsor Protocol Number: 2019-013-GLOB1 Start Date*: 2020-07-27
    Sponsor Name:Hutchison MediPharma Limited
    Full Title: A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients wit...
    Medical condition: Refractory metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FR (Completed) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) IT (Prematurely Ended) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003521-42 Sponsor Protocol Number: ARG-E08 Start Date*: 2017-02-09
    Sponsor Name:Mitsubishi Tanabe Pharma GmbH
    Full Title: SAICoDis – Safety of Argatroban Infusion in Conduction Disturbances. A prospective, open, multicenter safety study to investigate conduction disturbances in patients receiving argatroban therapy.
    Medical condition: Patients without diagnosed HIT II but with a coronary heart disease and with a diagnosed stable or unstable angina are planned for a percutaneous coronary intervention (PCI) according to clinical r...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003211 Arteriosclerosis coronary artery PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005792-12 Sponsor Protocol Number: GOIRC-06-2020 Start Date*: 2022-04-05
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: Pilot ‘Window of Opportunity’ Neoadjuvant Study of Abemaciclib in Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC)
    Medical condition: Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021961-61 Sponsor Protocol Number: VOS-AML-301 Start Date*: 2011-05-19
    Sponsor Name:Sunesis Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Controlled, Double Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or...
    Medical condition: Relapsed or refractory acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    20.0 100000004864 10054296 Acute myeloid leukemia NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) BE (Completed) HU (Completed) ES (Completed) IT (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001575-37 Sponsor Protocol Number: AT13387-05 Start Date*: 2014-12-15
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC).
    Medical condition: Non-small cell lung cancer (NSCLC) which represents 85% of all lung cancers.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002053-69 Sponsor Protocol Number: 3068A1-301-WW Start Date*: 2002-08-13
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: FRACTURE INCIDENCE REDUCTION AND SAFETY OF TSE-424 (BAZEDOXIFENE ACETATE) COMPARED TO PLACEBO AND RALOXIFENE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN
    Medical condition: Reduction of new vertebral fractures in osteoporotic postmenopausal women- Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005449-43 Sponsor Protocol Number: MORAb-003-003 PR Start Date*: 2009-10-29
    Sponsor Name:Morphotek, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory ...
    Medical condition: Platinum-Resistant or Refractory Relapsed Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 13:13:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA